SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Businessperson Walking Out With Exit Sign On Wall
Business
OncoSec Slashes Headcount by Almost Half, Goes All-In on Lead Candidate
OncoSec Medical Inc. announced Tuesday that it was laying off around 45% of its workforce to focus its resources on the development of its lead asset TAVO-EP.
October 5, 2022
 · 
2 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: EnPlusOne, Cellarity, Voyager and More
Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.
October 5, 2022
 · 
5 min read
 · 
Tristan Manalac
David L. Ryan/The Boston Globe via Getty Images
Drug Development
Pfizer, Clovis Make Inroads Against Tough to Treat Prostate Cancer
Early data from the Phase III TALAPRO-2 study showed Talzenna, Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients.
October 4, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
AAO 2022: Janssen, REGENXBIO, Apellis and More
Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.
October 3, 2022
 · 
3 min read
 · 
Tristan Manalac
Maddie Meyer/Getty Images
Business
Moderna Bolsters Leadership with New Execs to Support Upcoming Pipeline Push
As it gears up to launch several new products, Moderna has created a new leadership role and onboarded an industry veteran.
September 30, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Sanofi/Regeneron’s Duxipent Scores First US Approval for Prurigo Nodularis
The FDA has approved Regeneron and Sanofi’s Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, making it the first drug approved for this indication.
September 29, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Business
With $68M Series A, Pheon Breaks into Competitive ADC Space
Pheon Therapeutics launched with $63 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates.
September 28, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
Money on the Move: Eagle, Elucidata, Prime Medicine and More
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.
September 28, 2022
 · 
5 min read
 · 
Tristan Manalac
Bodo Marks/picture alliance via Getty
Drug Development
Lynparza Ovarian Cancer Withdrawal Latest in Series of PARP Inhibitor Setbacks
The announcement follows a subgroup analysis of the Phase III SOLO3 trial which showed patients treated with Lynparza saw a 33% greater risk of death than controls who received standard chemotherapy.
September 26, 2022
 · 
2 min read
 · 
Tristan Manalac
Bodo Marks/picture alliance via Getty Images
Business
AstraZeneca, Ionis Drop Hypercholesterolemia Candidate Despite Positive Mid-Stage Data
AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday.
September 23, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Michael Vi/Getty Images
Business
Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership
Allogene Therapeutics’ French partner Servier has withdrawn all involvement in the development of Allogene’s anti-CD19 products, allowing Allogene to license its CD19 products outside the U.S.
September 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Katherine Welles
Drug Development
Merck Resumes Trials on HIV Hopeful, But Drops PrEP Bid For Now
After enduring nine months of clinical holds, Merck announced that it is restarting the Phase III clinical program for islatravir, its candidate for people with HIV-1 infection.
September 21, 2022
 · 
3 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: Marinus, Evotec, Ventyx and more (Updated)
This week’s money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.
September 21, 2022
 · 
6 min read
 · 
Tristan Manalac
Drug Development
First Wave Embarks on Take Two in CF and Chronic Pancreatitis EPI
First Wave BioPharma announced that it is restarting its adrulipase program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.
September 20, 2022
 · 
2 min read
 · 
Tristan Manalac
Physiotherapist is measuring a plastic prosthesis on a patient's shoulder
Drug Development
COVID-19 Variants Potential Factor in Mixed Virios Fibromyalgia Results
Virios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia.
September 19, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More